TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer

Michael D. Nyquist, Yingming Li, Tae Hyun Hwang, Luke S. Manlove, Robert L. Vessella, Kevin A T Silverstein, Daniel F. Voytas, Scott M. Dehm

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Androgen receptor (AR) target genes direct development and survival of the prostate epithelial lineage, including prostate cancer (PCa). Thus, endocrine therapies that inhibit the AR ligand-binding domain (LBD) are effective in treating PCa. AR transcriptional reactivation is central to resistance, as evidenced by the efficacy of AR retargeting in castration-resistant PCa (CRPC) with next-generation endocrine therapies abiraterone and enzalutamide. However, resistance to abiraterone and enzalutamide limits this efficacy in most men, and PCa remains the second-leading cause of male cancer deaths. Here we show that AR gene rearrangements in CRPC tissues underlie a completely androgen-independent, yet AR-dependent, resistance mechanism. We discovered intragenic AR gene rearrangements in CRPC tissues, which we modeled using transcription activator-like effector nuclease (TALEN)-mediated genome engineering. This modeling revealed that these AR gene rearrangements blocked full-length AR synthesis, but promoted expression of truncated AR variant proteins lacking the AR ligand- binding domain. Furthermore, these AR variant proteins maintained the constitutive activity of the AR transcriptional program and a CRPC growth phenotype independent of full-length AR or androgens. These findings demonstrate that AR gene rearrangements are a unique resistance mechanism by which AR transcriptional activity can be uncoupled from endocrine regulation in CRPC.

Original languageEnglish (US)
Pages (from-to)17492-17497
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume110
Issue number43
DOIs
StatePublished - Oct 22 2013

Fingerprint

Gene Rearrangement
Androgen Receptors
Prostatic Neoplasms
Castration
Transcription Activator-Like Effector Nucleases
Androgens
Ligands

ASJC Scopus subject areas

  • General

Cite this

TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. / Nyquist, Michael D.; Li, Yingming; Hwang, Tae Hyun; Manlove, Luke S.; Vessella, Robert L.; Silverstein, Kevin A T; Voytas, Daniel F.; Dehm, Scott M.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, No. 43, 22.10.2013, p. 17492-17497.

Research output: Contribution to journalArticle

Nyquist, Michael D. ; Li, Yingming ; Hwang, Tae Hyun ; Manlove, Luke S. ; Vessella, Robert L. ; Silverstein, Kevin A T ; Voytas, Daniel F. ; Dehm, Scott M. / TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. In: Proceedings of the National Academy of Sciences of the United States of America. 2013 ; Vol. 110, No. 43. pp. 17492-17497.
@article{033782b4a8184f4aa128a2a206259786,
title = "TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer",
abstract = "Androgen receptor (AR) target genes direct development and survival of the prostate epithelial lineage, including prostate cancer (PCa). Thus, endocrine therapies that inhibit the AR ligand-binding domain (LBD) are effective in treating PCa. AR transcriptional reactivation is central to resistance, as evidenced by the efficacy of AR retargeting in castration-resistant PCa (CRPC) with next-generation endocrine therapies abiraterone and enzalutamide. However, resistance to abiraterone and enzalutamide limits this efficacy in most men, and PCa remains the second-leading cause of male cancer deaths. Here we show that AR gene rearrangements in CRPC tissues underlie a completely androgen-independent, yet AR-dependent, resistance mechanism. We discovered intragenic AR gene rearrangements in CRPC tissues, which we modeled using transcription activator-like effector nuclease (TALEN)-mediated genome engineering. This modeling revealed that these AR gene rearrangements blocked full-length AR synthesis, but promoted expression of truncated AR variant proteins lacking the AR ligand- binding domain. Furthermore, these AR variant proteins maintained the constitutive activity of the AR transcriptional program and a CRPC growth phenotype independent of full-length AR or androgens. These findings demonstrate that AR gene rearrangements are a unique resistance mechanism by which AR transcriptional activity can be uncoupled from endocrine regulation in CRPC.",
author = "Nyquist, {Michael D.} and Yingming Li and Hwang, {Tae Hyun} and Manlove, {Luke S.} and Vessella, {Robert L.} and Silverstein, {Kevin A T} and Voytas, {Daniel F.} and Dehm, {Scott M.}",
year = "2013",
month = "10",
day = "22",
doi = "10.1073/pnas.1308587110",
language = "English (US)",
volume = "110",
pages = "17492--17497",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "43",

}

TY - JOUR

T1 - TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer

AU - Nyquist, Michael D.

AU - Li, Yingming

AU - Hwang, Tae Hyun

AU - Manlove, Luke S.

AU - Vessella, Robert L.

AU - Silverstein, Kevin A T

AU - Voytas, Daniel F.

AU - Dehm, Scott M.

PY - 2013/10/22

Y1 - 2013/10/22

N2 - Androgen receptor (AR) target genes direct development and survival of the prostate epithelial lineage, including prostate cancer (PCa). Thus, endocrine therapies that inhibit the AR ligand-binding domain (LBD) are effective in treating PCa. AR transcriptional reactivation is central to resistance, as evidenced by the efficacy of AR retargeting in castration-resistant PCa (CRPC) with next-generation endocrine therapies abiraterone and enzalutamide. However, resistance to abiraterone and enzalutamide limits this efficacy in most men, and PCa remains the second-leading cause of male cancer deaths. Here we show that AR gene rearrangements in CRPC tissues underlie a completely androgen-independent, yet AR-dependent, resistance mechanism. We discovered intragenic AR gene rearrangements in CRPC tissues, which we modeled using transcription activator-like effector nuclease (TALEN)-mediated genome engineering. This modeling revealed that these AR gene rearrangements blocked full-length AR synthesis, but promoted expression of truncated AR variant proteins lacking the AR ligand- binding domain. Furthermore, these AR variant proteins maintained the constitutive activity of the AR transcriptional program and a CRPC growth phenotype independent of full-length AR or androgens. These findings demonstrate that AR gene rearrangements are a unique resistance mechanism by which AR transcriptional activity can be uncoupled from endocrine regulation in CRPC.

AB - Androgen receptor (AR) target genes direct development and survival of the prostate epithelial lineage, including prostate cancer (PCa). Thus, endocrine therapies that inhibit the AR ligand-binding domain (LBD) are effective in treating PCa. AR transcriptional reactivation is central to resistance, as evidenced by the efficacy of AR retargeting in castration-resistant PCa (CRPC) with next-generation endocrine therapies abiraterone and enzalutamide. However, resistance to abiraterone and enzalutamide limits this efficacy in most men, and PCa remains the second-leading cause of male cancer deaths. Here we show that AR gene rearrangements in CRPC tissues underlie a completely androgen-independent, yet AR-dependent, resistance mechanism. We discovered intragenic AR gene rearrangements in CRPC tissues, which we modeled using transcription activator-like effector nuclease (TALEN)-mediated genome engineering. This modeling revealed that these AR gene rearrangements blocked full-length AR synthesis, but promoted expression of truncated AR variant proteins lacking the AR ligand- binding domain. Furthermore, these AR variant proteins maintained the constitutive activity of the AR transcriptional program and a CRPC growth phenotype independent of full-length AR or androgens. These findings demonstrate that AR gene rearrangements are a unique resistance mechanism by which AR transcriptional activity can be uncoupled from endocrine regulation in CRPC.

UR - http://www.scopus.com/inward/record.url?scp=84886447413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886447413&partnerID=8YFLogxK

U2 - 10.1073/pnas.1308587110

DO - 10.1073/pnas.1308587110

M3 - Article

VL - 110

SP - 17492

EP - 17497

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 43

ER -